Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for MBX 4291 in Obesity. The expected timing is based on the latest available company guidance and may change.
6/16/25- IND submission. 9/4/25- First participant dosed. Topline data in 2027. 11/06/25:- Obesity Ph1 trial NCT07142707 MAD results expected Q4 2026. 03/12/26:- Phase 1 multiple ascending dose data for MBX 4291 remains on track to read out in Q4 2026. 05/07/26:- Obesity Day May 11, 2026 to show initial blinded Ph1 MBX 4291 data; MAD results still expected Q4 2026. 05/11/26:- Preliminary blinded Ph1 data showed 7% mean weight loss; 12-week MAD Part C data still Q4 2026. 08/06/26:- Ph1 MAD Part B showed 7% weight loss; Part C data remain Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.